Calls
2
Anukica Kim Constantino
CNBC Reporter
Win Rate
50.0%
return
-10.0%
Loading charts...
Ticker
Side
Mentions
First Call
Call Price
P&L
Thesis
Theme
Source
Long
Aug 19
$152.70
+0.5%
The first-ever Phase 3 trial of an mRNA-based personalized cancer vaccine combined with Merck's Keytruda reduced the risk of melanoma recurrence and spread versus Keytruda alone. Analysts say the results boost confidence that the shot could work across multiple cancer types and become a multi-billion-dollar product for both Merck and Moderna.
Pharma & Biotech
Long
Aug 19
$183.00
-20.4%
The first-ever Phase 3 trial of an mRNA-based personalized cancer vaccine combined with Merck's Keytruda reduced the risk of melanoma recurrence and spread versus Keytruda alone. Analysts say the results boost confidence that the shot could work across multiple cancer types and become a multi-billion-dollar product for both Merck and Moderna.
Pharma & Biotech
Showing 2 of 2 calls · sorted by mentions
Choose a mentions count to open ticker posts.
Anukica Kim Constantino has 2 trade ideas tracked on Buzzberg across 2 tickers since August 2026. Most covered: MRK, MRNA.
